Medical Policy

Electrical Stimulation Devices for Psychiatric and Neurological Conditions

Table of Contents
- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References
- Endnotes

Policy Number: 157
BCBSA Reference Number: N/A
NCD/LCD: NA

Related Policies
- Cranial Electrotherapy Stimulation – CES and Auricular Electrostimulation, #362
- Outpatient Electroconvulsive Therapy, #319
- Percutaneous Electrical nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT), #172
- Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders, #297
- Transcutaneous Electrical Nerve Stimulation (TENS), #003

Policy¹

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue℠ and Medicare PPO Blue℠ Members

Transcranial direct current stimulation devices (TDCS) are considered INVESTIGATIONAL for the treatment of all conditions including but not limited to brain and spinal cord injury, Parkinson’s disease and behavioral health conditions such as major depressive disorder, anxiety, substance use disorders, and post-traumatic stress disorder (PTSD).

Transcranial alternating current stimulation (TACS) devices are considered INVESTIGATIONAL for the treatment of all conditions including Parkinson’s disease, Alzheimer’s, Seizure disorders, and behavioral health conditions such as major depressive disorder, anxiety, substance use disorders, and post-traumatic stress disorder (PTSD).

External Trigeminal Nerve Stimulation (eTNS) devices are considered INVESTIGATIONAL for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).

INVESTIGATIONAL devices include but are not limited to:
- The Brain Stimulator v3.0
• The Brain Driver v2.1
• APEX Type A
• OMNI Stimulator
• TCT TDCS Device
• Soterix 1x1
• Focus V2 (TES)
• Focus V3
• NeuroConn DC Stimulator PLUS
• Activa Dose II Caputron
• Foc.us V2
• Monarch (eTNS).

Note: BCBSMA does not approve any medical devices that have not received FDA approval.

Prior Authorization Information

Inpatient
• For services described in this policy, precertification/preauthorization is required for all products if the procedure is performed inpatient.

Outpatient
• For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.

<table>
<thead>
<tr>
<th>CPT Codes / HCPCS Codes / ICD Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPT codes</strong></td>
</tr>
<tr>
<td>K1016</td>
</tr>
<tr>
<td>K1017</td>
</tr>
</tbody>
</table>

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The following HCPCS code is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

HCPCS Codes

Description
Transcranial direct current stimulation (TDCS) devices neurostimulation to specifically targeted areas of the brain through low levels of constant electric currents. TDCS devices deliver cathodal (negative) stimulation or anodal (positive) stimulation via small electrodes placed on different regions of the scalp and are thought to influence the rate of neuronal activity.
Transcranial alternating current stimulation (TACS) devices deliver neurostimulation to specifically targeted areas of the brain with alternating electoral currents. The alternating currents are thought to change the rate of abnormal neuronal activity that may be related to a variety of behavioral and cognitive conditions.

TDCS and TACS are non-invasive, painless treatments that are being evaluated for a variety of conditions including, chronic pain, brain and spinal cord injury, Parkinson's disease, and psychiatric conditions such as major depressive disorder, substance use disorders and anxiety. TDCS and TACS devices can be used in the home setting or in a therapeutic setting under the direction of a physician. TDCS and TACS devices can be manually set to the desired electrical current and length of time. Recommended time for treatment is 20-30 minutes of neurostimulation per session. Results from the treatments depend on how long the neurostimulation is delivered.

Some of the devices used for TDCS include The Brain Stimulator v3.0™, the APEX type A™, and the Omni Stimulator. Other devices include the Activa Dose II, The Brain Driver v2.1, and the NeuroConn. Some of the devices come with software that help improve reproducible neurostimulation levels and headbands that hold the electrodes in place during treatment. TACS devices include Soterix 1x1, Starstim, and the Brain Stimulator™.

External trigeminal nerve stimulation (eTNS) devices (Monarch™) deliver low levels of electrical stimulation to targeted areas of the brain thought to be associated with ADHD. eTNS devices are a minimally invasive approach that does not require the use of medication for the treatment of ADHD in the pediatric population and can be prescribed by a physician for in home use. Caretakers will apply the stimulation device to the patient while asleep. Current studies are evaluating the use of eTNS to reduce symptoms of ADHD, including hyperactivity, impulsivity, anxiety, affective reactivity and behavioral changes. Studies have also evaluated eTNS as a treatment for facial pain and migraine.

Summary
Transcranial Direct Current Stimulation (TDCS) and Transcranial Alternating Current Stimulation devices are being investigated for a variety of conditions including chronic pain, brain and spinal cord injury, Parkinson's disease and psychiatric conditions including major depressive disorder, anxiety, and post-traumatic stress disorder.

Small randomized controlled trials and multiple case studies have evaluated the use of TDCS and TACS devices in Parkinson’s and Alzheimer’s disease, major depressive disorder, anxiety and post-traumatic stress disorder (PTSD). While some of the studies showed small improvements in symptom reduction and increased mood, outcomes did not demonstrate clinically significant improvements in symptoms. The study designs and treatment protocols differed significantly and were not reproducible. The evidence is insufficient to determine the effects of this technology on health outcomes.

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/2021</td>
<td>Clarified coding information.</td>
</tr>
</tbody>
</table>

Information Pertaining to All Blue Cross Blue Shield Medical Policies
Click on any of the following terms to access the relevant information:
Medical Policy Terms of Use
Managed Care Guidelines
Indemnity/PPO Guidelines
References


4. Alonzo, A., Aaronson, S., Bikson, M. Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression.


Endnotes

1 Based on expert opinion